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Technical advances have enabled surgeons to
perform bypasses to small distal arteries. Femoral-
tibial saphenous vein grafts, with primary patency
rates up to 69% and secondary patency rates of 85%
at 5 years,1 have been the conduits of choice for the
lower extremity. When greater saphenous or alter-
nate veins are not available, prosthetic grafts have
been used for distal bypasses in selected patients.
However, these grafts have not provided acceptable
long-term results, motivating attempts to develop
small-diameter thromboresistant prosthetic grafts by
pretreatment with a variety of antithrombotic com-
pounds, including heparin.
In 1988, we encountered patients with heparin-
coated pulmonary artery catheters who developed
heparin-induced thrombocytopenia (HIT). The
thrombocytopenia remitted when the catheters were
removed and recurred when new heparin-coated
catheters were inserted. When segments of the
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Purpose: Thromboresistant synthetic grafts should decrease the frequency of graft
thromboses and could be useful in bypasses to small arteries and to arteries with com-
promised flow. Heparin-bonded grafts (HBG) have been developed. Studies were done
to determine whether the heparin bond is permanent and whether the HBG would
aggregate platelets in the presence of heparin-associated antiplatelet antibodies
(HAAbs).
Methods: We studied an 8 mm HBG from company A (HBGA) and 8 mm and 6 mm HBGs
from company B (HBGB-8 and HBGB-6), none of which is available for clinical use in the
United States. Five 1 cm long segments of HBGA, HBGB-8, and HBGB-6 were incubat-
ed for 24 hours in 5 ml of plasma, 10 ml of saline, or 10 ml of Ringer’s lactate. After incu-
bation, 1 ml was obtained from each solution and assayed for heparin. Segments of each
graft that leached off an equivalent of 1 U of heparin/ml (i.e., 1 mm2 of HBGA, 5 mm2
of HBGB-8, and 20 mm2 of HBGB-6) were incubated with 0.15 ml of plasma with
HAAbs (six samples per graft) for 30 minutes at 25° C. The grafts were removed, and 0.1
ml of normal-donor, platelet-rich plasma was added. The samples were placed in an aggre-
gometer and allowed to react until positive aggregation occurred or 27 minutes had
elapsed. Segments of non–heparin-bonded polyester grafts served as controls.
Results: Heparin leached off all grafts in plasma (mean values: HBGA, 83.4 U of
heparin/ml; HBGB-8, 4 U of heparin/ml; HBGB-6, 6.2 U of heparin/ml). In normal
saline, the mean heparin concentrations were lower (HBGA, 10.8 U of heparin/ml;
HBGB-8, 0 U of heparin/ml; HBGB-6, 0.01 U of heparin/ml. The mean heparin con-
centration after incubation in Ringer’s lactate were 10 U of heparin/ml for HBGA, 0 U
of heparin/ml HBGB-8, and 0.22 U of heparin/ml HBGB-6. All of the HBGs induced
platelet aggregation inHAAb-positive plasma. None of the control grafts induced
platelet aggregation in HAAb-positive plasma.
Conclusions: All HBGs leeched heparin into plasma, and all induced platelet aggregation
in the presence of HAAbs. The possibility of sensitizing patients to heparin leeching
from a HBG with the activation of platelets and secondary thrombosis strongly suggests
that HBG be used with great caution. Other methods for inducing graft thromboresis-
tance should be developed. (J Vasc Surg 1998;27:896-901.)
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heparin-coated catheters were incubated with plas-
ma from patients known to have heparin-associated
antiplatelet antibodies (HAAbs) and with normal-
donor platelet-rich plasma, platelet aggregation was
induced. We concluded that the heparin-coated
catheters must be removed from patients with HIT
if the thrombocytopenia was to be reversed and
complications avoided.2 We stopped using heparin-
coated pulmonary artery catheters.
We acquired collagen-coated, heparin-bonded
Dacron grafts for testing from two manufacturers.
The goals of this study were to determine if the
heparin remained permanently bound to the Dacron
grafts and to determine whether dissociated heparin
was capable of inducing platelet aggregation in the
presence of HAAbs.
METHODS
This study was approved by the Institutional
Review Board at the University of Missouri,
Columbia. Collagen-coated, heparin-bonded grafts
(HBGA) with 8 mm diameters were provided by
company A (Meadox Medicals, Inc., Oakland, N.J.)
for testing. We obtained collagen-coated HBGs with
8 mm (HBGB-8) and 6 mm (HBGB-6) diameters
that were manufactured by company B (Inter-
Vascular SA, LaCiotat, France).
One-centimeter-long segments of each graft were
soaked (6 hours at 25°C, 18 hours at 4°C) in
platelet-poor plasma (5 ml), normal saline (10 ml),
or Ringer’s lactate (10 ml). One milliliter of the dilu-
ent was withdrawn from each sample and assayed for
heparin. The grafts were also incubated under more
physiologic conditions (24 hours at 37°C) with sim-
ilar volumes of plasma, saline, and Ringer’s lactate.
The chromogenic heparin assay (Stachrom
Heparin, Diagnostica Stago, Asnieres-Ser-Seine,
France) was performed with the MLA 900C
Coagulation Analyzer (Medical Laboratory Auto-
mation, Inc., Pleasantville, N.Y.). The assay is based
on the ability of the heparin-antithrombin III com-
plex to inactivate a known amount of factor Xa.
Chromogenic substrate CBS 31.39 was used to
determine the amount of factor Xa present.
If heparin was detected in the diluent, platelet
aggregation assays were performed to determine
whether heparin in the presence of HAAbs was able
to induce platelet activation and aggregation. Each
graft was tested with six HAAb-positive plasma sam-
ples. The amount of graft that released approxi-
mately 1 unit of heparin per 1 ml of plasma was
determined. Each graft segment was first incubated
for 30 minutes at room temperature with 0.15 ml of
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HAAb-positive, platelet-poor plasma. The grafts
were removed, and 0.1 ml of normal-donor,
platelet-rich plasma was added. The mixture was
placed in an aggregometer (Chronolog Corpor-
ation, Haverton, Penn.) and allowed to react until
platelet aggregation occurred or until 27 minutes
had elapsed. The lag time, slope of the aggregation
curve, and percent change in optical density were
recorded. A positive aggregation result was defined
by a 20% decrease in optical density. Platelet aggre-
gation was confirmed by visual inspection. Our
method for assaying HAAb-induced platelet aggre-
gation has been reported elsewhere.3
Higher concentrations of heparin were used to
eliminate false-positive reactions caused by nonspe-
cific binding between heparin and platelets.4 The
higher concentrations of heparin were obtained
from larger segments of HBGA, from which approx-
imately 100 U of heparin per 1 ml of plasma were
released. If aggregation did not occur, adenosine
diphosphate (10–4 M) was added to the mixture to
eliminate false-negative results caused by nonreac-
tive donor platelets.3
Platelet aggregation testing for the HBGA graft
was performed in a blinded fashion. Group 1 (n = 9)
consisted of HBGs, and group II (n = 10) consisted
of grafts without heparin. Graft segments of 1 mm2
in each group were placed in an aggregometer and
tested for the ability to induce platelet aggregation
in the presence of HAAbs.
Statistical comparison of dissociated heparin
from grafts in plasma, normal saline, and Ringer’s
Table I. Amount of heparin leaching off grafts
after incubation for 6 hours at room temperature
and 18 hours at 4°C
Lactated 
Ringer’s
Grafts Plasma* Saline* solution*
HBGA 83.4 ± 10.9† 10.8 ± 1.72 10.0 ± 0
HBGB-8 4.0 ± 0‡ 0 0
HBGB-6 6.2 ± 0.4§ 0.01 ± 0.007 0.22 ± 0.04
HBGA, Heparin-bonded graft from company A; HBGB, heparin-
bonded grafts from company B.
*All values are given as the average units of heparin/ml ± SD.
† Significantly greater heparin concentration in plasma than in
saline (p = 0.0001) or in lactated Ringer’s solution (p = 0.00002).
No significant difference was observed between saline and
Ringer’s lactate (p = 0.3).
‡ Significantly greater heparin concentration in plasma than in
saline (p = 0) or in Ringer’s lactate (p = 0).
§ Significantly greater heparin concentration in plasma than in
saline (p = 0.000006) or in Ringer’s lactate (p = 0.000008).
lactate was made with the two-tailed, paired t test.
The two-tailed Mann-Whitney test compared
platelet aggregation induced by porcine heparin
with aggregation induced by the heparin dissociated
from the grafts. Significant differences were defined
as a p value of less than 0.05.
RESULTS
Meadox grafts and covalent linkage of
heparin. Heparin dissociated from the HBGA graft
in plasma, normal saline, and Ringer’s lactate. The
average concentrations of heparin detected were
83.4 U/ml in plasma, 10.8 U/ml in normal saline,
and 10.0 U/ml in Ringer’s lactate (Table I). No
heparin was detected when incubations were per-
formed with the Meadox control grafts.
When segments of each HGBA graft (heparin
dissociation equivalent to 1 U/ml) were used in
aggregation studies, all HBGs induced platelet
aggregation in HAAb-positive plasma (Table II).
When aggregation assays were performed with
larger segments of graft (heparin dissociation
equivalent to 100 U/ml), no platelet aggregation
occurred. Control grafts did not induce platelet
aggregation in the presence of HAAb-positive
plasma.
The blinded platelet aggregation study results
revealed that all group I grafts (HBGA, n = 9)
induced platelet aggregation in HAAb-positive plas-
ma and that all group II grafts (company A, no
heparin bonding, n = 10) failed to induce platelet
aggregation in HAAb-positive plasma.
InterVascular SA grafts and ionic attachment
of heparin. The HBGB-8 and HBGB-6 prosthetics,
prepared by InterVascular SA, were incubated (6
hours at 25° C, 18 hours at 4° C) in plasma, normal
saline, and Ringer’s lactate. Solutions were assayed
for heparin. When the HBGB-8 grafts were incubat-
ed, heparin was detected in the plasma (4 U/ml) but
not in normal saline or Ringer’s lactate. The HBGB-
6 grafts released heparin with an average of 6.2 U/ml
in plasma, 0.01 U/ml in normal saline, and 0.22
U/ml in Ringer’s lactate (Table I).
Segments of each graft that released an equiva-
lent of 1 U of heparin per 1 ml of plasma were incu-
bated in HAAb-positive plasma and tested for their
ability to induce platelet aggregation. All HBGB-8
and HBGB-6 grafts induced platelet aggregation in
HAAb-positive plasma (Table II).
When the grafts were incubated for 24 hours in
plasma, normal saline, and Ringer’s lactate at 37° C,
heparin was detected in the HBGA diluents at con-
centrations of 90 U/ml in plasma, 110 U/ml in
saline, and 115 U/ml in Ringer’s lactate. The con-
centrations of heparin released by the HBGB-8 solu-
tion were 15 U/ml in plasma, 0.11 U/ml in saline,
and 0.41 U/ml in Ringer’s lactate; those of the
HBGB-6 incubations were 14 U/ml in plasma, 0.19
U/ml in saline, and 0.62 U/ml in Ringer’s lactate.
Platelet aggregometry was also performed with
porcine heparin (Solopak) used as a positive control.
The platelet aggregation tracings induced by the
HBGs were similar to those induced by 1 U/ml of
the porcine heparin (Table II). All p values were
greater than 0.05.
DISCUSSION
The search for artificial thromboresistant sur-
faces using heparin began with heparin bonding on
colloidal graphite surfaces.5 These products were
found to be unstable in blood. This finding
prompted development of other techniques of
heparin bonding to provide increased stability and
retention of anticoagulant properties. Ionic, multi-
point covalent, and end-point attachment tech-
niques have been developed to attach heparin to
graft surfaces.
Heparin is a linear sulfated polysaccharide with
alternating 1,4-linked uronic acid and glucosamine
residues. Heparin binds to the plasma protein
antithrombin and potentiates the inhibitory effects
of the antithrombin on plasma serine proteases.6
The antithrombin binding sequence of surface-
immobilized heparin must be preserved for it to
maintain its thromboresistant properties.
The effect of bonding heparin through a glu-
taraldehyde-stabilized ionic complex on the early
thrombogenicity of polyurethane grafts and expand-
ed polytetrafluoroethylene grafts (PTFE) and the
effect of covalent bonding of heparin on PTFE
grafts were studied in sheep. The “stabilized ionic
bonding” of heparin significantly reduced the early
thrombogenicity of polyurethane but had little
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Table II. Percent platelet aggregation after incu-
bation
Grafts Porcine heparin (%)* Graft heparin (%)*
HBGA 58.5 ± 19.0 50.5 ± 13.0
HBGB-8 50.0 ± 20.3 46.5 ± 21.1
HBGB-6 44.2 ± 25.7 18.3 ± 12.2
HBGA, Heparin-bonded graft from company A; HBGB, heparin-
bonded grafts from company B.
*Average percentage ± SD of platelet aggregation after incuba-
tion with heparin-bonded grafts (on the basis of the dissociation
of 1 unit of heparin per ml).
effect on PTFE grafts; however, the thrombogenici-
ty of the latter was markedly decreased after covalent
bonding of heparin. The grafts were perfused for 4
hours.7 The graft surfaces and the sheep plasma sam-
ples were not assayed for heparin.
Heparin can bind to collagen by covalent link-
age. Carbodiimide (hydrogen cyanamide) activates
the carboxyl groups of heparin, allowing covalent
binding of heparin to the amino groups of collagen.
A slurry of collagen powder, heparin, and carbodi-
imide in a 1:1:1 weight ratio (25° C, pH 4.85) cre-
ates an immobilized heparin preparation. However,
spectrophotometric heparin assays demonstrate that
the percent immobilized heparin activity decreased
by 20% at 16.5 days in vitro.8
Swartbol and Norgren9 analyzed the quantity of
heparin retention on heparin-bonded, collagen-
coated knitted Dacron grafts (HCD) and heparin-
bonded, non–collagen-coated knitted Dacron grafts
(HD) after they had been exposed to shear stress in
an artificial circulation model. HCD grafts showed
no loss of heparin from the graft surface when
exposed to a flow of 200 ml/minute with saline for
up to 168 hours. HD grafts demonstrated an initial
loss of heparin from 8 to 3 mg/g per graft segment
within 1 week, after which the level remained con-
stant during the remaining 3 weeks.9 In this case,
the heparin was assayed by measurement of total
sugars.
Heparinized surfaces have been prepared by
covalently coupling heparin with the graft through
an end group.10 Covalent end-point attachment
leaves more active heparin sites available than ionic
or multipoint covalent attachment. With end-point
attachment techniques, about one sixth of the end-
point attached heparin fragments carry the
antithrombin sequence11 and are available to bind
plasma protein antithrombin. Suppression of factor
XII activation and enhanced antithrombin inhibition
of thrombin and factor Xa have been demonstrated
in small-diameter polyethylene tubing that was
modified by end-point attachment of heparin.12,13
The modified polyethylene tubing was tested for
heparin leakage and found to be leak free after a 60-
minute exposure to normal plasma.13
We were asked by Meadox Medicals, Inc., to eval-
uate the stability of heparin, bonded by multipoint
covalent attachment to HCDs. We also studied
HBGs with an ionic attachment of heparin through a
quaternary ammonium complex (TDMAC-heparin
complex), manufactured by InterVascular SA. Our
study demonstrated that heparin dissociated from the
HCD prepared by both companies and caused
platelet aggregation in the presence of HAAbs.
Meadox Medicals, Inc., elected not to market their
HBGs.
All grafts leached heparin into plasma with
overnight incubation at low temperatures. At the
physiologic temperature of 37° C, dissociation of
heparin from the grafts increased. Low temperatures
were chosen to decrease the effects of bacterial con-
tamination, and 37° C was chosen to simulate phys-
iologic conditions. We speculate that the increased
release of heparin in plasma at the physiologic tem-
perature resulted from the presence of endogenous
proteases. All HBGs induced platelet aggregation in
HAAb-positive plasma. The non–heparin-bonded
grafts failed to induce platelet aggregation in HAAb-
positive plasma.
HIT is an immune disorder in which HAAbs
activate platelets in the presence of heparin. Platelet
activation may result in platelet aggregation with
thrombocytopenia and in arterial and venous throm-
bosis. All patients receiving pork, beef, or low-mo-
lecular-weight heparins are at risk for developing
HIT. It can occur in patients receiving small
amounts of heparin, such as heparin flushes for intra-
venous catheters or leaching from heparin-coated
central catheters.2 In the presence of heparin and the
immune complex, the antibodies induce platelet
aggregation with thrombocytopenia and thrombot-
ic complications (rarely, bleeding). HBGs that leach
heparin into the bloodstream place the patient at risk
for HIT. Patients with HBGs who develop throm-
bocytopenia should be tested for HAAbs.
The most important aspect of the management
of patients with HIT is prompt discontinuation of
the exposure to heparin. The placement of a
heparin-bonded vascular prosthesis poses a manage-
ment problem if the patient develops HAAbs. The
high morbidity and mortality rates associated with
HIT mandate that patients receive no more heparin,
at least until the HAAbs are no longer detectable. To
accomplish cessation of exposure to heparin, graft
removal with alternate revascularization, if indicated,
must be undertaken if the thrombocytopenia is to be
reversed and complications avoided.
Although heparin can be attached to grafts and
the HBGs can retain thromboresistant properties,
“permanent” bonding of heparin to synthetic grafts
has not been accomplished. The results of this study
demonstrate that heparin dissociates from covalent-
ly bonded and ionically attached heparin in collagen-
coated Dacron prostheses and that the dissociated
heparin causes platelet aggregation in the presence
of HAAbs.
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Dr. John R. Hoch (Madison, Wis.). I would like to
congratulate Dr. Almeida and his colleagues for an inter-
esting and thought-provoking series of experiments and
for highlighting the potential danger of heparin-bonded
vascular grafts. Since the early 1970s, Dr. Silver and his
colleagues frequently have expanded our knowledge of
heparin-induced thrombocytopenia and its potential for
severe thromboembolic complications. Recent studies
have documented that patients with heparin-induced
thrombocytopenia have antibodies that are directed
against a complex of heparin and platelet factor 4 released
from the alpha granules of platelets. However, the fre-
quency with which antibodies of the different classes are
formed, their relationship to clinical disease, and the
importance of antibody titer symptomatology have not
been defined. Of clinical importance, though, is the fact
that patients may become sensitized to heparin with only
limited exposures.
As Dr. Almeida said, Dr. Silver previously has demon-
strated that, in patients with heparin-induced thrombocy-
topenia, heparin-coated pulmonary artery catheters cause
persistent thrombocytopenia in spite of removal of all
other sources of heparin. In that paper, heparin-induced
thrombocytopenia was reversed only after removal of the
heparin-coated catheters. The concern of Dr. Almeida and
his colleagues that led to the current investigation is that
heparin may leech off of heparin-bonded graft surfaces
and then sensitize patients, which would result in the pro-
duction of heparin-associated antibodies and the risk of
thromboembolic complication.
The fundamental management of heparin-induced
thrombocytopenia requires cessation of heparin exposure,
which would translate to graft removal. Dr. Almeida
obtained heparin-bonded collagen-coated Dacron grafts
from two manufacturers. The goal of his study was to
determine if heparin was permanently bonded to the
Dacron, and if not, to determine whether the dissociated
heparin was capable of inducing platelet aggregation in the
presence of heparin-associated antibodies. Heparin was
found to leech off of all graft samples incubated in plasma
over a 24-hour period. The graft from company A
appeared to release a higher concentration of heparin than
those from company B, although no statistics are present-
ed. Graft samples then were incubated for 30 minutes in
the presence of platelet-poor plasma from six patients with
heparin-induced thrombocytopenia. Dr. Almeida, can you
supply any further details regarding how these six patients
were selected?
Although platelet-aggregation assay is the test most
widely used to diagnose heparin-induced thrombocytope-
nia, the assay may have lower specificity than currently
available enzyme-linked immunosorbent assays for the
heparin platelet factor 4 complex. Would you also review
the clinical criteria that are used today at the University of
DISCUSSION
Some questions remain unanswered. What is the
duration of the heparin leaching? Will heparin leach-
ing from the grafts sensitize patients and stimulate
them to produce HAAbs? We suspect that it will. We
are concerned that HAAb-negative patients may
become sensitized and develop HAAbs during their
long exposures to implanted HBGs and that HAAb-
positive patients, when exposed to the leached
heparin, may develop HIT.
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Missouri to identify patients at risk for heparin-induced
thrombocytopenia? The authors found that the heparin
that dissociated from the graft surface led to platelet
aggregation in all instances.
Control grafts did not induce platelet aggregation in
the presence of heparin antibody-positive plasma. Porcine
heparin was used as an internal control and always induced
aggregation. However, the percent aggregation varied
widely between experiments within the same antibody-
positive plasma group treated with the control porcine
heparin. Is this variant significant, or we should be focus-
ing on the mere presence or absence of aggregation? These
experiments clearly show dissociation of heparin that was
covalently bound to collagen-coated Dacron. Is the idea of
heparin bonding to biomaterials dead? If future manufac-
turing efforts by industry ensure a stable heparin bond,
would these grafts then be safe? In other words, does the
heparin have to leech off the graft to pose a risk to the
patient? In an attempt to answer this question, has your
laboratory examined pulmonary artery catheters with this
newer chromogenic heparin assay to document whether or
not heparin dissociates from these catheters? These
catheters clinically have been shown to potentiate heparin-
induced thrombocytopenia. Although Dr. Almeida has
demonstrated that the dissociation of heparin from these
grafts can result in platelet aggregation when exposed to
heparin-associated antibodies, he cannot draw conclusions
regarding the potential for this small amount of heparin to
sensitize patients and leech the development of heparin-
induced thrombocytopenia. Unfortunately, animal models
of heparin-induced thrombocytopenia in which heparin-
bonded biomaterials can be adequately tested have not
been developed. Thus, I agree with the authors that the
safest course at present would be for industry to abandon
their efforts to decrease graft thrombin genicity by
attempting to bond heparin to the luminal surface.
I enjoyed this important paper, and would like to
thank the Midwestern Vascular Surgical Society for invit-
ing me to discuss it.
Dr. Jose I Almeida. I will try to be brief. You asked
how we determined whether a patient is at risk.
Traditionally, any patient receiving heparin with a 30% fall
in their platelet count would be suspected and tested. We
currently feel that any fall in platelet count in a patient
receiving heparin places that patient at risk. Blood samples
from those patients are sent for platelet aggregation 
testing.
To answer your next question, we accept a 20%
decrease in optical density as indicating positive platelet
aggregation. 
Does heparin have to leech off the grafts to sensitize
patients? We do not know; this study certainly does not
answer that question. We have not studied the new pul-
monary artery catheters yet but will be doing so in the
very near future. 
In regards to your first question about enzyme-linked
immunosorbent assays test, we have spent several years
trying to develop a reliable ELISA test. However, we have
yet to find one that is dependable. The platelet aggrega-
tion assay remains the standard at our institution.
I wish to thank the membership for the privilege of
presenting and discussing this paper.
